You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Future directions in therapeutic interventions for conjunctival inflammatory disorders

Pflugfelder, Stephen C; Stern, Michael E

Current Opinion in Allergy & Clinical Immunology:
doi: 10.1097/ACI.0b013e3282ef69e3
Eye allergy
Abstract

Purpose of review: To review recent advances in pathogenesis and treatment of conjunctival inflammatory disorders.

Recent findings: The conjunctiva becomes inflamed in a number of conditions, including allergy, atopy, dry eye, mucus membrane pemphigoid, Stevens-Johnson syndrome and surgical manipulation. Basic and clinical studies have identified a number of inflammatory mediators as potential therapeutic targets in these conditions. Additionally, new therapeutic agents and enhanced delivery systems have been evaluated.

Summary: Increased understanding of the key mediators of conjunctival inflammation coupled with improved drug delivery methods are leading to more effective therapy for conjunctival inflammatory disorders.

Author Information

aOcular Surface Center, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA

bBiological Sciences, Allergan, Inc., Irvine, California, USA

Correspondence to Stephen C. Pflugfelder, MD, Cullen Eye Insititute, 6565 Fannin, NC 205, Houston, TX 77030, USA fax: +1 713 798 1457; e-mail: stevenp@bcm.tmc.edu

Copyright © 2007 Wolters Kluwer Health, Inc. All rights reserved.